戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 s predicted a greater or lesser benefit from gemtuzumab ozogamicin.
2 d by azacitidine, 75 mg/m(2) for 7 days, and gemtuzumab ozogamicin, 3 mg/m(2) on day 8, in older pati
3 ceive an initial dose of the immunoconjugate gemtuzumab ozogamicin (6 mg/m(2) intravenously).
4  less than 3.5 months after the last dose of gemtuzumab ozogamicin; 6 (40%) developed VOD.
5 ated the safety and efficacy of single-agent gemtuzumab ozogamicin, a humanized anti-CD33 antibody-ta
6  Liver injury developed in 11 patients after gemtuzumab ozogamicin administration; it was manifested
7 r patients benefit from the incorporation of gemtuzumab ozogamicin, an anti-CD33 mAb toxin, into indu
8                                              Gemtuzumab ozogamicin, an immunoconjugate of an anti-CD3
9 utilization of two leukaemia-directed ADCs - gemtuzumab ozogamicin and inotuzumab ozogamicin - as wel
10 e development of therapeutic ADCs, including gemtuzumab ozogamicin and inotuzumab ozogamicin, provide
11 for which there are substantial literatures: gemtuzumab ozogamicin and inotuzumab ozogamicin; and tra
12 t Pgp plays a role in clinical resistance to gemtuzumab ozogamicin and suggest that treatment trials
13 both Mylotarg(TM) (antibody-drug conjugate - gemtuzumab ozogamicin) and Rapamune(R) (sirolimus nanocr
14        Antibody-directed therapy by means of gemtuzumab ozogamicin as an adjunct to induction chemoth
15                                              Gemtuzumab ozogamicin can be safely added to conventiona
16 ples from relapsed AML patients eligible for gemtuzumab ozogamicin clinical trials were assayed for P
17          Antibody-targeted chemotherapy with gemtuzumab ozogamicin (CMA-676, a CD33-targeted immunoco
18                                    Mylotarg (gemtuzumab ozogamicin, CMA-676; Wyeth-Ayerst Laboratorie
19                              The addition of gemtuzumab ozogamicin did not increase the proportion of
20 out a single dose of the monoclonal antibody gemtuzumab ozogamicin, followed by autologous stem-cell
21 wed the course of 23 patients who were given gemtuzumab ozogamicin for AML that had relapsed after he
22 pt has been reinvigorated by the approval of gemtuzumab ozogamicin for treatment of acute myeloid leu
23  May 1, 2013, that included an assessment of gemtuzumab ozogamicin given to adults (aged 15 years and
24 Induction 2 consisted of ADE with or without gemtuzumab ozogamicin (GO anti-CD33 monoclonal antibody)
25 ated the efficacy and toxicity of sequential gemtuzumab ozogamicin (GO) and standard chemotherapy in
26 ) and arsenic trioxide (ATO) with or without gemtuzumab ozogamicin (GO) but without traditional cytot
27                                              Gemtuzumab ozogamicin (GO) contains an anti-CD33 antibod
28                           Emerging data with gemtuzumab ozogamicin (GO) demonstrate target validity a
29  Food and Drug Administration (FDA) approved gemtuzumab ozogamicin (GO) for the treatment of adults w
30               We investigated treatment with gemtuzumab ozogamicin (GO) in 51 patients aged 65 years
31 ndomized phase 3 trial evaluating the use of gemtuzumab ozogamicin (GO) in an intensive consolidation
32 ated the efficacy of this regimen with added gemtuzumab ozogamicin (GO) in high-risk patients.
33                   The encouraging results of gemtuzumab ozogamicin (GO) in newly diagnosed AML, and p
34 1 provides a rationale for the evaluation of gemtuzumab ozogamicin (GO) in this AML entity.
35                                              Gemtuzumab ozogamicin (GO) is a novel immunoconjugate th
36                                              Gemtuzumab ozogamicin (GO) is an immunoconjugate between
37 stic impact of NPM1mut MRD and the effect of gemtuzumab ozogamicin (GO) on NPM1mut TLs and the cumula
38 igated the impact of the CD33-targeted agent gemtuzumab ozogamicin (GO) on survival in pediatric pati
39 y Group (SWOG), which tested the addition of gemtuzumab ozogamicin (GO) to a 317 regimen in a randomi
40                                  Addition of gemtuzumab ozogamicin (GO) to induction chemotherapy imp
41 val for the majority of patients when adding gemtuzumab ozogamicin (GO) to induction chemotherapy.
42 lar events on the benefit of the addition of gemtuzumab ozogamicin (GO) to standard front-line chemot
43 ted the potential benefit of the addition of gemtuzumab ozogamicin (GO) to standard induction and pos
44                                     In 2000, gemtuzumab ozogamicin (GO) was granted accelerated appro
45                                      Purpose Gemtuzumab ozogamicin (GO), a CD33-targeted immunoconjug
46                                              Gemtuzumab ozogamicin (GO), a monoclonal antibody used i
47  (AML) leukemic blasts and is the target for gemtuzumab ozogamicin (GO), a toxin-conjugated anti-CD33
48                                              Gemtuzumab ozogamicin (GO), an immunoconjugate of an ant
49 ction chemotherapy, with one or two doses of gemtuzumab ozogamicin (GO).
50 oid leukemia (AML) blasts and is targeted by gemtuzumab ozogamicin (GO).
51           The antibody-targeted therapeutic, gemtuzumab ozogamicin (GO, Mylotarg), is approved for tr
52 n the role of postconsolidation therapy with gemtuzumab ozogamicin (GO; Mylotarg) in children with ac
53                                              Gemtuzumab ozogamicin (GO; Mylotarg), a novel immunoconj
54 side (ADE) (n = 465) and the augmented ADE + gemtuzumab ozogamicin (GO; n = 466) arms of AAML0531 tri
55                                        While gemtuzumab ozogamicin (GTMZ) is commonly used in the tre
56      CD33-directed antibody-drug conjugates (gemtuzumab ozogamicin) have been shown to improve overal
57                                     In vitro gemtuzumab ozogamicin--induced apoptosis was also evalua
58 atic sinusoidal liver injury developed after gemtuzumab ozogamicin infusion.
59 ilure or sepsis at a median of 40 days after gemtuzumab ozogamicin infusion.
60 hat was sustained for at least 60 days after gemtuzumab ozogamicin infusion.
61         Emerging clinical data indicate that gemtuzumab ozogamicin is efficacious not only for acute
62  effective agents, such as purine analogs or gemtuzumab ozogamicin, is still under investigation, whe
63 eatment of acute myeloid leukemia (AML) with gemtuzumab ozogamicin may result in liver injury.
64      Such agents include the immunoconjugate gemtuzumab ozogamicin, multidrug resistance inhibitors,
65                                              Gemtuzumab ozogamicin (Mylotarg) targets leukemia cells
66 momab-131I (Bexxar), and one drug conjugate, gemtuzumab ozogamicin (Mylotarg), are now on the market.
67 oconjugates of calicheamicin, exemplified by gemtuzumab ozogamicin (Mylotarg), is a clinically valida
68 e anthracycline, adding other agents such as gemtuzumab ozogamicin, or through 'timed sequential' the
69 isease, 19; refractory disease, 10) received gemtuzumab ozogamicin ranging from 6 to 9 mg/m2 per dose
70          However, the contribution of Pgp to gemtuzumab ozogamicin resistance is poorly defined.
71           These data suggest that the use of gemtuzumab ozogamicin should be reassessed and its licen
72                     However, the addition of gemtuzumab ozogamicin significantly reduced the risk of
73 tion of sinusoidal collagen, suggesting that gemtuzumab ozogamicin targets CD33(+) cells residing in
74 tor); the anti-CD33 antibody-drug conjugate, gemtuzumab ozogamicin; the oral, poorly absorbable hypom
75 atient data to assess the efficacy of adding gemtuzumab ozogamicin to induction chemotherapy in adult
76               However, survival benefit from gemtuzumab ozogamicin was not associated with MFC-MRD ch
77                                              Gemtuzumab ozogamicin was relatively well tolerated at 6
78 geting the CD33 differentiation antigen with gemtuzumab ozogamicin was the first attempt of such an a
79                                              Gemtuzumab ozogamicin was the first example of antibody-
80       Using the CD33 antibody-drug conjugate Gemtuzumab Ozogamicin, we show resistance of engrafted,
81  and suggest that treatment trials combining gemtuzumab ozogamicin with MDR reversal agents are warra
82 concomitant azole antifungal prophylaxis and gemtuzumab ozogamicin with the first course of chemother
83 mbines CD33-targeted CAR-T cells, or the ADC Gemtuzumab Ozogamicin with the transplantation of hemato